{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T05:58:55Z","timestamp":1790747935782,"version":"4.1.0"},"reference-count":75,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2007,12,1]],"date-time":"2007-12-01T00:00:00Z","timestamp":1196467200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Best Practice & Research Clinical Haematology"],"published-print":{"date-parts":[[2007,12]]},"DOI":"10.1016\/j.beha.2007.08.003","type":"journal-article","created":{"date-parts":[[2008,4,17]],"date-time":"2008-04-17T16:33:54Z","timestamp":1208450034000},"page":"613-624","source":"Crossref","is-referenced-by-count":50,"title":["Pathophysiology of myeloma bone disease"],"prefix":"10.1016","volume":"20","author":[{"given":"Flavia R.","family":"Esteve","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. David","family":"Roodman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.beha.2007.08.003_bib1","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1016\/S0301-472X(99)00061-2","article-title":"Cell Biology of the osteoclast","volume":"27","author":"Roodman","year":"1999","journal-title":"Experimental Hematology"},{"key":"10.1016\/j.beha.2007.08.003_bib2","doi-asserted-by":"crossref","unstructured":"Roodman GD. Treatment strategies for bone disease. Bone Marrow Transplantation 2007 Aug 6. [Epub ahead of print].","DOI":"10.1038\/sj.bmt.1705802"},{"key":"10.1016\/j.beha.2007.08.003_bib3","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1634\/stemcells.2005-0220","article-title":"A crosstalk between myeloma cells and marrow stromal cells stimulates production of DKK1 and interleukin-6: a potential role in the development of lytic bone disease and tumor progression in multiple myeloma","volume":"24","author":"Gunn","year":"2006","journal-title":"Stem Cells"},{"key":"10.1016\/j.beha.2007.08.003_bib4","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.exphem.2004.03.015","article-title":"New insight in the mechanism of osteoclast activation and formation in\u00a0multiple myeloma: focus on the receptor activator NF-Kappa-B ligand (RANKL)","volume":"32","author":"Giuliani","year":"2004","journal-title":"Experimental Hematology"},{"key":"10.1016\/j.beha.2007.08.003_bib5","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1182\/blood.V96.2.671","article-title":"Macrophage inflammatory protein 1-alpha is a potential osteoclast stimulatory factor in multiple myeloma","volume":"96","author":"Choi","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.beha.2007.08.003_bib6","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.1182\/blood-2003-06-1992","article-title":"IL-3 expression by myeloma cells increases both osteoclast formation and growth of myeloma cells","volume":"103","author":"Lee","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.beha.2007.08.003_bib7","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1073\/pnas.96.7.3540","article-title":"Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand","volume":"96","author":"Hsu","year":"1999","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.beha.2007.08.003_bib8","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1006\/bbrc.1998.9788","article-title":"RANK is the essential signaling receptor for osteoclast differentiation factor in osteoclastogenesis","volume":"253","author":"Nakagava","year":"1998","journal-title":"Biochemical and Biophysical Research Communications"},{"key":"10.1016\/j.beha.2007.08.003_bib9","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/nature01658","article-title":"Osteoclast differentiation and activation","volume":"423","author":"Boyle","year":"2003","journal-title":"Nature"},{"key":"10.1016\/j.beha.2007.08.003_bib10","doi-asserted-by":"crossref","first-page":"3597","DOI":"10.1073\/pnas.95.7.3597","article-title":"Osteoclast differentiation factor is a ligand for osteoprotegerin\/osteoclastogenesis-inhibitory factor and is identical to TRANCE\/RANKL","volume":"95","author":"Yasuda","year":"1998","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.beha.2007.08.003_bib11","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1530\/eje.0.1390152","article-title":"Osteoprotegerin and its cognate ligand: a new paradigm of osteoclastogenesis","volume":"139","author":"Hofbauer","year":"1998","journal-title":"European Journal of Endocrinology"},{"key":"10.1016\/j.beha.2007.08.003_bib12","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1006\/bbrc.1998.8610","article-title":"Osteoclast differentiation factor mediates an essential signal for bone resorption induced by 1 alpha, 25-dihydroxyvitamin D3, prostaglandin E2, or parathyroid hormone in the microenvironment of bone","volume":"246","author":"Tsukii","year":"1998","journal-title":"Biochemical and Biophysical Research Communications"},{"key":"10.1016\/j.beha.2007.08.003_bib13","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1101\/gad.13.18.2412","article-title":"RANK is essential for osteoclast and lymph node development","volume":"13","author":"Dougall","year":"1999","journal-title":"Genes & Development"},{"key":"10.1016\/j.beha.2007.08.003_bib14","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0092-8674(00)81569-X","article-title":"Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation","volume":"93","author":"Lacey","year":"1998","journal-title":"Cell"},{"key":"10.1016\/j.beha.2007.08.003_bib15","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0092-8674(00)80209-3","article-title":"Osteoprotegerin: a novel secreted protein involved in the regulation of bone density","volume":"89","author":"Simonet","year":"1997","journal-title":"Cell"},{"key":"10.1016\/j.beha.2007.08.003_bib16","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1101\/gad.12.9.1260","article-title":"Osteoprotegerin deficient mice develop early onset osteoporosis and arterial calcification","volume":"12","author":"Bucay","year":"1998","journal-title":"Genes & Development"},{"key":"10.1016\/j.beha.2007.08.003_bib17","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1073\/pnas.97.4.1566","article-title":"RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism","volume":"97","author":"Li","year":"2000","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.beha.2007.08.003_bib18","doi-asserted-by":"crossref","first-page":"11581","DOI":"10.1073\/pnas.201394498","article-title":"Multiple myeloma disrupts the TRANCE\/osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression","volume":"98","author":"Pearse","year":"2001","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.beha.2007.08.003_bib19","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1182\/blood-2003-02-0380","article-title":"Soluble receptor activator of nuclear factor kappaB ligand- osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index","volume":"102","author":"Terpos","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.beha.2007.08.003_bib20","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1046\/j.1365-2141.2002.03257.x","article-title":"Myeloma interacts with the bone marrow microenvironment to induce osteoclastogenesis and is dependent on osteoclast activity","volume":"116","author":"Yaccoby","year":"2002","journal-title":"British Journal of Haematology"},{"key":"10.1016\/j.beha.2007.08.003_bib21","doi-asserted-by":"crossref","first-page":"3349","DOI":"10.1182\/blood.V97.11.3349","article-title":"Macrophage inflammatory protein-1 alpha is an osteoclastogenic factor in myeloma that is independent of receptor activator of nuclear factor kappaB ligand","volume":"97","author":"Han","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.beha.2007.08.003_bib22","doi-asserted-by":"crossref","first-page":"4998","DOI":"10.1182\/blood-2002-11-3385","article-title":"Gene expression profiling of multiple myeloma reveals molecular portraits in relation to the pathogenesis of the disease","volume":"101","author":"Magrangeas","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.beha.2007.08.003_bib23","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/j.1365-2141.2004.04864.x","article-title":"Ability of myeloma cells to secrete macrophage inflammatory protein (MIP)-1 alpha and MIP-1beta correlates with lytic bone lesions in patients with multiple myeloma","volume":"125","author":"Hashimoto","year":"2004","journal-title":"British Journal of Haematology"},{"key":"10.1016\/j.beha.2007.08.003_bib24","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1182\/blood.V87.4.1495.bloodjournal8741495","article-title":"Development of an in vivo model of human multiple myeloma bone disease","volume":"87","author":"Alsina","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.beha.2007.08.003_bib25","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1172\/JCI200113116","article-title":"Antisense inhibition of macrophage inflammatory protein 1 alpha block bone destruction in a model of myeloma bone disease","volume":"108","author":"Choi","year":"2001","journal-title":"The Journal of Clinical Investigation"},{"key":"10.1016\/j.beha.2007.08.003_bib26","doi-asserted-by":"crossref","first-page":"3465","DOI":"10.1182\/blood-2006-04-017087","article-title":"MIP-1a (CCL3) is a downstream target of FGFR3 and RAS-MAPK signaling in multiple myeloma","volume":"108","author":"Masih-Khan","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.beha.2007.08.003_bib27","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1182\/blood-2005-03-1080","article-title":"IL-3 is a potential inhibitor of osteoblast differentiation in multiple myeloma","volume":"106","author":"Ehrlich","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.beha.2007.08.003_bib28","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1002\/ajh.2830390303","article-title":"Radioimmunoassay for the measurement of serum IL-6 and its correlation with tumour cell mass parameters in multiple myeloma","volume":"39","author":"Solary","year":"1992","journal-title":"American Journal of Hematology"},{"key":"10.1016\/j.beha.2007.08.003_bib29","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1046\/j.1365-2141.1998.00687.x","article-title":"Interleukin -6 is expressed by plasma cells from patients with multiple myeloma and monoclonal gammopathy of unknown significance","volume":"101","author":"Sai","year":"1998","journal-title":"British Journal of Haematology"},{"key":"10.1016\/j.beha.2007.08.003_bib30","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1046\/j.1365-2141.2000.01845.x","article-title":"Human myeloma cells promote the production of interleukin-6 by primary human osteoblasts","volume":"108","author":"Karadag","year":"2000","journal-title":"British Journal of Haematology"},{"key":"10.1016\/j.beha.2007.08.003_bib31","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1182\/blood-2003-11-3839","article-title":"Osteoclasts enhance myeloma cell growth and survival via cell to cell contact: a vicious cycle between bone destruction and myeloma expansion","volume":"104","author":"Abe","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.beha.2007.08.003_bib32","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1016\/j.yexcr.2006.02.026","article-title":"Normalizing the bone marrow microenvironment with p38 inhibitor reduces multiple myeloma cell proliferation and adhesion and suppresses osteoclast formation","volume":"312","author":"Nguyen","year":"2006","journal-title":"Experimental Cell Research"},{"key":"10.1016\/j.beha.2007.08.003_bib33","doi-asserted-by":"crossref","first-page":"981a","DOI":"10.1182\/blood.V108.11.3436.3436","article-title":"Inhibition of p38a MAPK reduces tumor burden, prevents the development of myeloma bone disease, and increases survival in the 5T2 and 5T3 murine models of myeloma","volume":"108","author":"Vanderkerken","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.beha.2007.08.003_bib34","doi-asserted-by":"crossref","first-page":"155a","DOI":"10.1182\/blood.V108.11.513.513","article-title":"targeting p62 in marrow stromal cells is effective at inhibiting myeloma cell growth","volume":"108","author":"Kurihara","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.beha.2007.08.003_bib35","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1200\/JCO.1989.7.12.1909","article-title":"Mechanisms of bone destruction in multiple myeloma: the importance of an unbalanced process in determining the severity of lytic bone disease","volume":"7","author":"Bataille","year":"1989","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.beha.2007.08.003_bib36","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1111\/j.1365-2141.1990.tb07904.x","article-title":"Osteoblast stimulation in multiple myeloma lacking bone lytic lesions","volume":"76","author":"Bataille","year":"1990","journal-title":"British Journal of Haematology"},{"key":"10.1016\/j.beha.2007.08.003_bib37","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1359\/jbmr.1999.14.2.256","article-title":"Marked osteoblastopenia and reduced bone formation in a model of multiple myeloma bone disease in severe combined immunodeficiency mice","volume":"14","author":"Hjorth-Hansen","year":"1999","journal-title":"Journal of Bone and Mineral Research"},{"key":"10.1016\/j.beha.2007.08.003_bib38","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1210\/en.2004-1343","article-title":"Mini review: transcriptional regulation in development of bone","volume":"146","author":"Kobayashi","year":"2005","journal-title":"Endocrinology"},{"key":"10.1016\/j.beha.2007.08.003_bib39","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S0092-8674(00)80257-3","article-title":"Osf2\/Cbfal: a transcriptional activator of osteoblast differentiation","volume":"89","author":"Ducy","year":"1997","journal-title":"Cell"},{"key":"10.1016\/j.beha.2007.08.003_bib40","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1002\/jcb.10369","article-title":"Regulation of the osteoblast specific transcription factor, Runx2: responsiveness to multiple signal transduction pathways","volume":"88","author":"Franceschi","year":"2003","journal-title":"Journal of Cellular Biochemistry"},{"key":"10.1016\/j.beha.2007.08.003_bib41","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S8756-3282(99)00111-8","article-title":"Cbfal as a regulator of osteoblast differentiation and function","volume":"25","author":"Karsenty","year":"1999","journal-title":"Bone"},{"key":"10.1016\/j.beha.2007.08.003_bib42","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/jcb.10276","article-title":"Runx2, a multifunctional transcription factor in skeletal development","volume":"87","author":"Komori","year":"2002","journal-title":"Journal of Cellular Biochemistry"},{"key":"10.1016\/j.beha.2007.08.003_bib43","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1182\/blood-2004-12-4986","article-title":"Myeloma cells block RUNX2\/CBFAL1 activity in human bone marrow osteoblast progenitors and inhibit osteoblast formation and differentiation","volume":"106","author":"Giuliani","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.beha.2007.08.003_bib44","doi-asserted-by":"crossref","first-page":"25163","DOI":"10.1074\/jbc.M000322200","article-title":"The osteoblast-specific transcription factor Cbfal contributes to the expression of osteoprotegerin, a potent inhibitor of osteoclast differentiation and function","volume":"275","author":"Thirunavukkarasu","year":"2000","journal-title":"The Journal of Biological Chemistry"},{"key":"10.1016\/j.beha.2007.08.003_bib45","doi-asserted-by":"crossref","first-page":"3151","DOI":"10.1182\/blood.V86.8.3151.3151","article-title":"Myeloma cells upregulate interleukin-6 secretion in osteoblastic cells through cell to cell contact but downregulate osteocalcin","volume":"86","author":"Barille","year":"1995","journal-title":"Blood"},{"key":"10.1016\/j.beha.2007.08.003_bib46","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/S0002-9440(10)62556-4","article-title":"Expression of CD56\/neural cell adhesion molecule correlates with the presence of lytic bone lesions in multiple myeloma and distinguishes myeloma from monoclonal gammopathy of undetermined significance and lymphomas with plasmacytoid differentiation","volume":"160","author":"Ely","year":"2002","journal-title":"The American Journal of Pathology"},{"key":"10.1016\/j.beha.2007.08.003_bib47","doi-asserted-by":"crossref","first-page":"6270s","DOI":"10.1158\/1078-0432.CCR-06-0845","article-title":"New Potential targets for treating myeloma bone disease","volume":"12","author":"Roodman","year":"2006","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/j.beha.2007.08.003_bib48","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1359\/jbmr.060117","article-title":"Interleukin-7 influences osteoclast function in vivo but is not a critical factor in ovariectomy-induced bone loss","volume":"21","author":"Lee","year":"2006","journal-title":"Journal of Bone and Mineral Research"},{"key":"10.1016\/j.beha.2007.08.003_bib49","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1073\/pnas.0136772100","article-title":"IL-7 induces bone loss in vivo by induction of receptor activator of nuclear factor kappaB ligand and tumor necrosis factor alpha from T cells","volume":"100","author":"Toraldo","year":"2003","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.beha.2007.08.003_bib50","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1038\/sj.onc.1206239","article-title":"Wnt signaling in B cell neoplasia","volume":"22","author":"Qiang","year":"2003","journal-title":"Oncogene"},{"key":"10.1016\/j.beha.2007.08.003_bib51","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/S0092-8674(01)00571-2","article-title":"LDL receptor-related protein (LRP5) affects bone accrual and eye development","volume":"107","author":"Gong","year":"2001","journal-title":"Cell"},{"key":"10.1016\/j.beha.2007.08.003_bib52","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.gene.2004.06.044","article-title":"Wnt signaling in osteoblasts and bone diseases","volume":"341","author":"Westerndorf","year":"2004","journal-title":"Gene"},{"key":"10.1016\/j.beha.2007.08.003_bib53","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1359\/jbmr.2003.18.10.1842","article-title":"BMP-2 controls alkaline phosphatase expression and osteoblast mineralization by a Wnt autocrine loop","volume":"18","author":"Rawadi","year":"2003","journal-title":"Journal of Bone and Mineral Research"},{"key":"10.1016\/j.beha.2007.08.003_bib54","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/S1534-5807(01)00041-7","article-title":"Dickkopf1 is required for embryonic head induction and limb morphogenesis in the mouse","volume":"1","author":"Mukhopadhyay","year":"2001","journal-title":"Developmental Cell"},{"key":"10.1016\/j.beha.2007.08.003_bib55","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1093\/emboj\/21.5.966","article-title":"The Wnt antagonist Dickkopf-1 is regulated by Bmp signaling and c-Jun and modulated programmed cell death","volume":"21","author":"Grotewold","year":"2002","journal-title":"The EMBO Journal"},{"key":"10.1016\/j.beha.2007.08.003_bib56","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1359\/jbmr.060311","article-title":"Deletion of a single allele of the Dkk-1 gene leads to an increase in bone formation and bone mass","volume":"21","author":"Morvan","year":"2006","journal-title":"Journal of Bone and Mineral Research"},{"key":"10.1016\/j.beha.2007.08.003_bib57","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.bone.2006.03.017","article-title":"Dkk-1 mediated inhibition of Wnt signaling in bone results in osteopenia","volume":"39","author":"Li","year":"2006","journal-title":"Bone"},{"key":"10.1016\/j.beha.2007.08.003_bib58","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1056\/NEJMoa030847","article-title":"The role of Wnt signaling antagonist DKK-1 in the development of osteolytic lesions in multiple myeloma","volume":"349","author":"Tian","year":"2003","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.beha.2007.08.003_bib59","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1002\/ijc.22033","article-title":"Serum concentrations of Dickkopf-1 protein are increased in patients with multiple myeloma and reduced after autologous stem cell transplantation","volume":"119","author":"Politou","year":"2006","journal-title":"International Journal of Cancer"},{"key":"10.1016\/j.beha.2007.08.003_bib60","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.devcel.2005.02.017","article-title":"Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation","volume":"8","author":"Glass","year":"2005","journal-title":"Developmental Cell"},{"key":"10.1016\/j.beha.2007.08.003_bib61","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1242\/jcs.02883","article-title":"Wnt signaling in osteoblasts regulates expression of the receptor activator of NFkappaB ligand and inhibits osteoclastogenesis in vitro","volume":"119","author":"Spencer","year":"2006","journal-title":"Journal of Cell Science"},{"key":"10.1016\/j.beha.2007.08.003_bib62","doi-asserted-by":"crossref","first-page":"3160","DOI":"10.1182\/blood-2004-12-4940","article-title":"Myeloma cells suppress bone formation by secreting a soluble Wnt inhibitor sFRP-2","volume":"106","author":"Oshima","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.beha.2007.08.003_bib63","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1002\/cncr.11133","article-title":"Receptor activator of NF-kappaB ligand, macrophage inflammatory protein 1-alpha and the proteasome","volume":"97","author":"Oyajobi","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.beha.2007.08.003_bib64","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1056\/NEJM199602223340802","article-title":"Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group","volume":"334","author":"Berenson","year":"1996","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.beha.2007.08.003_bib65","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.4065\/81.8.1047","article-title":"mayo clinic consensus statement for the use of bisphosphonates in multiple myeloma","volume":"81","author":"Lacy","year":"2006","journal-title":"Mayo Clinic proceedings"},{"key":"10.1016\/j.beha.2007.08.003_bib66","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1158\/1078-0432.CCR-05-1933","article-title":"A study of the biological receptor activator of nuclear factor kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer","volume":"12","author":"Body","year":"2006","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/j.beha.2007.08.003_bib67","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1124\/jpet.105.100362","article-title":"Inhibition of p38 mitogen-activated protein kinase prevents inflammatory bone destruction","volume":"317","author":"Mbalaviele","year":"2006","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/j.beha.2007.08.003_bib68","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1089\/jir.2006.26.719","article-title":"MKK3\/6-p38 MAPK signaling is required for IL-1 beta and TNF alpha induced RANKL expression in bone marrow stromal cells","volume":"26","author":"Rossa","year":"2006","journal-title":"Journal of Interferon & Cytokine Research"},{"key":"10.1016\/j.beha.2007.08.003_bib69","doi-asserted-by":"crossref","first-page":"109","DOI":"10.3816\/CLM.2006.n.047","article-title":"Response to bortezomib and activation of osteoblasts in multiple myeloma","volume":"7","author":"Zangari","year":"2006","journal-title":"Clinical Lymphoma & Myeloma"},{"key":"10.1016\/j.beha.2007.08.003_bib70","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1111\/j.1600-0609.2006.00692.x","article-title":"Bortezomib increases osteoblast activity in myeloma patients irrespective of response to treatment","volume":"77","author":"Heider","year":"2006","journal-title":"European Journal of Haematology"},{"key":"10.1016\/j.beha.2007.08.003_bib71","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1172\/JCI16198","article-title":"Selective inhibitors of the osteoblast proteasome stimulate bone formation in vivo and in vitro","volume":"111","author":"Garrett","year":"2003","journal-title":"The Journal of Clinical Investigation"},{"key":"10.1016\/j.beha.2007.08.003_bib72","doi-asserted-by":"crossref","first-page":"153a","DOI":"10.1182\/blood.V108.11.506.506","article-title":"Bortezomib reduces serum dicckopf-1 and RANKL concentrations and normalizes indices of bone remodeling in patients with relapsed multiple myeloma","volume":"108","author":"Terpos","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.beha.2007.08.003_bib73","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.exphem.2004.11.015","article-title":"MIP-1 alpha utilizes both CCR1 and CCR5 to induce osteoclast formation and increase adhesion of myeloma cells to marrow stromal cells","volume":"3","author":"Oba","year":"2005","journal-title":"Experimental Hematology"},{"key":"10.1016\/j.beha.2007.08.003_bib74","doi-asserted-by":"crossref","first-page":"3568","DOI":"10.1182\/blood-2002-08-2383","article-title":"Macrophage inflammatory protein 1-alpha triggers migration and signaling cascades mediating survival and proliferation in multiple myeloma cells","volume":"101","author":"Lentzsch","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.beha.2007.08.003_bib75","doi-asserted-by":"crossref","first-page":"154a","DOI":"10.1182\/blood.V108.11.509.509","article-title":"PTH and Bortezomib suppress growth of primary human myeloma cells through increased bone formation in vivo","volume":"108","author":"Pennisi","year":"2006","journal-title":"Blood"}],"container-title":["Best Practice & Research Clinical Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692607000655?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692607000655?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,4]],"date-time":"2020-05-04T12:39:32Z","timestamp":1588595972000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521692607000655"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,12]]},"references-count":75,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2007,12]]}},"alternative-id":["S1521692607000655"],"URL":"https:\/\/doi.org\/10.1016\/j.beha.2007.08.003","relation":{},"ISSN":["1521-6926"],"issn-type":[{"value":"1521-6926","type":"print"}],"subject":[],"published":{"date-parts":[[2007,12]]}}}